Seeing is believing: The impact of structural genomics on antimicrobial drug discovery

Nature Reviews Microbiology

Volumn 2, Issue 9, 2004, Pages 739-746

  Schmid, Molly B ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; DOXYCYCLINE; KANAMYCIN; KETOLIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBOSOME PROTEIN; RIFADEN; RIFAMPICIN; RIFAMYCIN; RNA POLYMERASE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG CLASSIFICATION; DRUG IDENTIFICATION; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENE MUTATION; GENE SEQUENCE; GENE TECHNOLOGY; GENOMICS; HUMAN; MICROBIAL GENETICS; MOLECULAR MODEL; NATURAL SELECTION; NONHUMAN; ORTHOLOGY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DATABASE; PROTEIN STRUCTURE; STRUCTURAL GENE; STRUCTURE ACTIVITY RELATION; TIME;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PROTEINS; BIOMEDICAL RESEARCH; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENOMICS; MODELS, MOLECULAR; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY;

EID: 4444295503     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro978     Document Type: Article

References (67)

1. Wilson, J. C. & von Itzstein, M. Recent strategies in the search for new anti-influenza therapies. Curr. Drug Targets 4, 389-408 (2003).
2. Hardy, L. W. & Maliyakil, A. The impact of structure-guided drug design on clinical agents. Curr. Drug Discov. [online] http://www.currentdrugdiscovery.com/pdf/2003/515563.pdf (2003).
3. Wimberly, B. T. et al. Structure of the 30S ribosomal subunit. Nature 407, 327-339 (2000).
4. Yusupov, M. M. et al. Crystal structure of the ribosome at 5.5 Å resolution. Science 292, 883-896 (2001).
5. Ban, N., Nissen, P., Hansen, J., Moore, P. B. & Steitz, T. A. The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. Science 289, 905-920 (2000).
6. Murakami, K. S., Masuda, S. & Darst, S. A. Structural basis of transcription initiation: RNA polymerase holoenzyme at 4 Å resolution. Science 296, 1280-1284 (2002).
7. Lim, D. & Strynadka, N. C. Structural basis for the β-lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nature Struct. Biol. 9, 870-876 (2002).
8. Bellon, S. et al. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob. Agents Chemother. 48, 1856-1864 (2004).
9. Tsai, F. T. et al. The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins 28, 41-52 (1997).
10. Bower, J. et al. Structure-based design of agents targeting the bacterial ribosome. Bioorg. Med. Chem. Lett. 13, 2455-2458 (2003).
11. Fleischmann, R. D. et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496-512 (1995).
12. Zalacain, M. et al. A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function. J. Mol. Microbiol. Biotechnol. 6, 109-126 (2004).
13. Alkerley, B. J. et al. A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc. Natl Acad. Sci. USA 99, 966-971 (2002).
14. Jacobs, M. A. et al. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA 100, 14339-14344 (2003).
15. Gerdes, S. Y. et al. Experimental determination and system level analysis of essential genes in Escherichia coli MG1655. J. Bacteriol. 185, 5673-5684 (2003).
16. Forsyth, R. A. et al. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 43, 1387-1400 (2002).
17. Sittampalam, G. S., Kahl, S. D. & Janzen, W. P. High-throughput screening: advances in assay technologies. Curr. Opin. Chem. Biol. 1, 384-391 (1997).
18. Silverman, L., Campbell, R. & Broach, J. R. New assay technologies for high-throughput screening. Curr. Opin. Chem. Biol. 2, 397-403 (1998).
19. Zhang, L. et al. Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene 255, 297-305 (2000).
20. Payne, D. et al. Discovery of a novel and potent class of Fabl-directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118-3124 (2002).
21. DeVito, J. A. et al. An array of target-specific screening strains for antibacterial discovery. Nature Biotechnol. 20, 478-483 (2002).
22. Bostian, K. A. & Schmid, M. B. in Antibacterial Therapy: Achievements, Problems and Future Perspectives (eds Busse, W. D., Zeiler, H. J. & Labischinski, H.) 61-68 (Springer Verlag, Berlin, 1997).
23. Ji, Y. et al. Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol. Lett. 231, 177-184 (2004).
24. Hou, J., Sims, G. E., Zhang, C. & Kim, S. H. A global representation of the protein fold space. Proc. Natl Acad. Sci. USA 100, 2386-2390 (2003).
25. Service, R. F. Structural genomics. Tapping DNA for structures produces a trickle. Science 298, 948-950 (2002).
26. Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235-242 (2000).
27. Lesley, S. A. et al. Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc. Natl Acad. Sci. USA 99, 11664-11669 (2002).
28. Christendat, D. et al. Structural proteomics of an archaeon. Nature Struct. Biol. 7, 903-909 (2000).
29. Goulding, C. W. & Perry, L. J. Protein production in Escherichia coli for structural studies by X-ray crystallography. J. Struct. Biol. 142, 133-143 (2003).
30. Vincentelli, R. et al. Medium-scale structural genomics: strategies for protein expression and crystallization. Acc. Chem. Res. 36, 165-172 (2003).
31. Gerstein, M. Patterns of protein-fold usage in eight microbial genomes: A comprehensive structural census. Proteins 33, 518-534 (1998).
32. Derewenda, Z. S. Rational protein crystallization by mutational surface engineering. Structure 12, 529-535 (2004).
33. Goulding, C. W. et al. Structural genomics of Mycobacterium tuberculosis: a preliminary report of progress at UCLA. Biophys. Chem. 105, 361-370 (2003).
34. Gerstein, M., Edwards, A., Arrowsmith, C. H. & Montelione, G. T. Structural genomics: current progress. Science 299, 1663 (2003).
35. Westbrook, J., Feng, Z., Chen, L., Yang, H. & Berman, H. M. The protein data bank and structural genomics. Nucleic Acids Res. 31, 489-491 (2003).
36. Makrides, S. C. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol Rev. 60, 512-538 (1996).
37. Jancarik, J. & Kim, S.-H. Sparse matrix sampling: a screening method for crystallization of proteins. J. Appl. Cryst. 24, 409-411 (1991).
38. Kimber, M. S. et al. Data mining crystallization databases: knowledge-based approaches to optimize protein crystal screens. Proteins 51, 562-568 (2003).
39. Goh, C. S. et al. Mining the structural genomics pipeline: identification of protein properties that affect high-throughput experimental analysis. J. Mol. Biol. 336, 115-130 (2004).
40. Hosfield, D. et al. A fully integrated protein crystallization platform for small molecule drug discovery. J. Struct. Biol. 142, 207-217 (2003).
41. Chayen, N. E. Protein crystallization for genomics: throughput versus output. J. Struct. Funct. Genomics 4, 115-120 (2003).
42. Rupp, B. High-throughput crystallography at an affordable cost: the TB structural genomics consortium crystallization facility. Acc. Chem. Res. 36, 173-181 (2003).
43. Moult, J., Fidelis, K., Zemla, A. & Hubbard, T. Critical assessment of methods of protein structure prediction (CASP)-round V. Proteins 53, S334-S339 (2003).
44. Venclovas, C., Zemla, A., Fidelis, K. & Moult, J. Assessment of progress over the CASP experiments. Proteins 53, S585-S595 (2003).
45. DeWeese-Scott, C. et al. Molecular modeling of protein function regions. Proteins 55, 942-961 (2004).
46. Daines, R. A. et al. First X-ray co-crystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling. J. Med. Chem. 46, 5-8 (2003).
47. Sharff, A. & Jhoti, H. High-throughput crystallography to enhance drug discovery. Curr Opin. Chem. Biol. 7, 340-345 (2003).
48. Whittington, D. A., Rusche, K. M., Shin, H., Fierke, C. A. & Christianson, D. W. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. Proc. Natl Acad. Sci. USA 100, 8146-8150 (2003).
49. Burley, S. K. The FAST and the curious: fragment-based lead discovery and optimization via high-throughput X-ray crystallography. Modern Drug Discov. 7, 53-55 (2004).
50. Hajduk, P. J. et al. A strategy for high-throughput assay development using leads derived from nuclear magnetic resonance-based screening. J. Biomol. Screen 7, 429-432 (2002).
51. Erlanson, D. A., McDowell, R. S. & O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 47, 3463-3482 (2004).
52. Nienaber, V. L. et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nature Biotechnol. 18, 1105-1108 (2000).
53. Sanders, W. J. et al. Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. J Med Chem. 47, 1709-1718 (2004).
54. Kline, T. et al. Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC. J. Med. Chem. 45, 3112-3129 (2002).
55. Onishi, H. R. et al. Antibacterial agents that inhibit lipid A biosynthesis. Science 274, 980-982 (1996).
56. Chen, M. H. et al. Carbohydroxamide-oxalidonones: antibacterial agents that target lipid A biosynthesis. Bioorg. Med. Chem. Lett. 9, 313-318 (1999).
57. Coggins, B. E., Li, X., Hindsgaul, O., Raetz, C. R. & Zhou, P. Assignment of the 1H, 13C and 15N resonances of the LpxC deacetylase from Aquifex aeolicus in complex with the substrate-analog inhibitor TU-514. J. Biomol NMR 28, 201-202 (2004).
58. Coggins, B. E. et al. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor. Nature Struct. Biol. 10, 645-651 (2003).
59. Qiu, X. et al. Crystal structure of Staphylococcus aureus tyrosyl-tRNA synthetase in complex with a class of potent and specific inhibitors. Protein Sci. 10, 2008-2016 (2001).
60. Payne, D. J. et al. Discovery of a novel and potent class of Fabl-directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118-3124 (2002).
61. Chen, L. et al. TargetDB: a target registration database for structural genomics projects. Bioinformatics (in the press).
62. Balzarini, J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr. Top. Med. Chem. 4, 921-944 (2004).
63. Nezami, A. & Freire, E. The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. Int. J. Parasitol. 32, 1669-1676 (2002).
64. Stammers, D. K. et al. 2.0 Å X-ray structure of the ternary complex of 7,8-dihydro-6-hydroxymethylpterinpyro-phosphokinase from Escherichia coli with ATP and a substrate analogue. FEBS Lett. 456, 49-53 (1999).
65. Smith, C. V. & Sacchettini, J. C. Mycobacterium tuberculosis: a model system for structural genomics. Curr. Opin. Struct. Biol. 13, 658-664 (2003).
66. Abergel, C. et al. Structural genomics of highly conserved microbial genes of unknown function in search of new antibacterial targets. J. Struct. Funct. Genomics 4, 141-157 (2003).
67. Wang, R., Fang, X., Lu, Y. & Wang, S. The PDBbind database: collection of binding affinities for protein - ligand complexes with known three-dimensional structures. J. Med. Chem. 47, 2977-2980 (2004).